Abstract
Seventeen alpha hydroxyprogesterone caproate (17-OHPC) is the only FDA-approved drug labeled for prevention of preterm delivery. This drug is also available as a compounded product from licensed compounding pharmacies. This article reviews the FDA approval history and pharmacy compounding quality control data of 17-OHPC, as well as briefly discusses possible future pharmaceutical development strategies for 17-OHPC.
Introduction
Preterm birth, defined as delivery before 37 weeks of gestation, remains a leading cause of neonatal morbidity and mortality in the United States, affecting approximately one in eight births. Seventeen alpha hydroxyprogesterone caproate (17-OHPC) is currently the only FDA-approved pharmacological intervention to reduce the risk of recurrent preterm birth in high-risk pregnancies. However, the clinical availability of 17-OHPC has been complicated by significant price increases following the 2011 approval of the brand-name product, Makena. This economic shift led many clinicians to rely on compounded versions of the drug, sparking a debate over quality control, stability, and professional liability.
Regulatory History and the Compounding Landscape
The regulatory journey of 17-OHPC began in 1956 with the approval of Delalutin. Over the decades, various formulations and manufacturers entered the market until the eventual discontinuation of many products, leading to the 2011 approval of Makena.
Under Section 503A of the Federal Food, Drug, and Cosmetic (FD&C) Act, licensed pharmacies are permitted to compound drugs for individual patients based on valid prescriptions. This practice became essential for maintaining patient access to 17-OHPC when the cost of the approved product rose from approximately $15 to $1,500 per injection.
Quality Assessment of Compounded 17-OHPC
A central concern regarding compounded 17-OHPC is whether these products meet the same rigorous quality standards as FDA-approved versions. This review synthesizes quality testing data from the FDA, KV Pharmaceutical (the manufacturer of Makena), and independent laboratory surveys.
While KV Pharmaceutical reported higher failure rates in compounded samples, independent analysis and FDA reports suggest that the "quality gap" is narrower than often claimed. When prepared correctly by licensed pharmacies, compounded 17-OHPC generally meets acceptable standards for potency, sterility, and pyrogenicity. Furthermore, the dry-heat sterilization often used in compounding can achieve a Sterility Assurance Level (SAL) of $10^{-6}$, which is technically superior to the $10^{-3}$ level achieved by the filtration sterilization used for the brand-name product.
Pharmaceutical Properties and Stability
17-OHPC is a highly lipophilic molecule (LogP of 5.88), classified as a BCS Class II drug due to its low aqueous solubility and high permeability. This lipophilicity necessitates the current oil-based intramuscular injection format. Stability studies indicate that compounded 17-OHPC remains stable for up to 56 weeks under various conditions, including exposure to heat and light, although it is sensitive to strong alkaline environments.
Research also suggests that 17-OHPC remains stable without the addition of benzyl alcohol. Eliminating this preservative could reduce local skin reactions at the injection site and minimize potential risks associated with benzyl alcohol exposure in pregnant women and neonates.
Pharmacokinetics and Dosing Considerations
The drug exhibits an exceptionally long half-life of approximately 16 days and a massive volume of distribution (up to 69,600 L), indicating significant sequestration in adipose tissue. Clinical data shows that trough plasma concentrations are significantly lower in women with higher BMIs. This suggests that the current "one-size-fits-all" weekly 250mg dose may be suboptimal for some patients, highlighting a need for personalized dosing regimens.
Future Development Strategies
The current reliance on painful, weekly intramuscular oil injections presents a barrier to patient compliance. Future pharmaceutical development should explore:
- Alternative Delivery Routes: Given its high lipophilicity, 17-OHPC is an excellent candidate for transdermal or vaginal delivery, which could bypass first-pass metabolism and improve patient comfort.
- Personalized Medicine: Investigating the impact of BMI and metabolic enzymes (such as CYP3A) on drug levels to tailor dosing to individual patient needs.
- Mechanistic Research: Further study is required to understand exactly how 17-OHPC prevents preterm labor, focusing on its effects on fetal membranes and uterine contractility.
Summary updated